FIG. 1.

Neurome’s drug target discovery approach. A: An example of the experimental paradigm employed to study disease-specific selective vulnerability. Amyloid plaque staining is shown in regions of the lateral (orange shading) and medial entorhinal cortices from an AD transgenic mouse model. B: Technology platforms used at Neurome, Inc. to analyze disease vulnerability and resistance in neuronal populations and mouse inbred strains. Experimental data provide candidate therapeutic targets and disease-modifying alleles that can be further assessed and validated with studies in animal disease models and in vitro assays. The research pipeline is designed to evaluate multiple disease models across all platforms in parallel.